We have made a comparison between ESG and LSG for weight loss. We have observed the patient who has undergone ESG and LSG at an interval of 1month and 6month.
Endoscopic Sleeve Gastroplasty (ESG) – It is a new form of weight-loss procedure in which the weight is reduced by reducing the size of the stomach. It is a type of non-surgical treatment.
Laparoscopic Sleeve Gastrectomy (LSG) – In this process, the size of the stomach is reduced by removing a part of the stomach. It is a type of surgical procedure.
Background and Aim
Endoscopic Sleeve Gastroplasty (ESG) reduces the gastric lumen to a size comparable with that of laparoscopic sleeve gastrectomy (LSG).
Our study compared the 6-month weight loss outcomes and adverse events of ESG with LSG in a case-matched group.
We retrospectively reviewed patients undergoing ESG and LSG at the same hospital.
We have prospectively collected data after the treatment.
Weight was recorded at an interval of 1 and 6 months after the treatment.
We have also recorded adverse or hostile events like new-onset gastroesophageal reflux disease (GERD)
A total of 54 ESG patients were matched with 83 LSG patients by age, sex, and mass index.
During the first month after the ESG and LSG treatment. The percentage of patients with GERD at baseline was similar in the two groups.
(16.7% in ESG group vs 25.3% in LSG group, P= 0.27)
After the six months follow up %TBWL compared with baseline was significantly lower in the ESG group compared with the LSG group. (17.1% vs 23.6%, P<0.01).
Hence, ESG patients had significantly lower rates of adverse events as compared with LSG patients (5.2% vs. 16.9%, P<0.05).
New-onset gastroesophageal reflux disease (GERD) was also significantly lower in the ESG group compared with the LSG group (1.9% vs. 14.5%, P<0.05).
After the complete study, it is observed that ESG is a minimally invasive on the same-day of treatment achieved less weight loss at six months than LSG, with the warning that LSG caused more adverse events and new-onset GERD than ESG.